Impatto dei polimorfismi genetici del CYP3A sui livelli plasmatici di carbamazepina

Translated title of the contribution: Impact of CYP3A polymorphism on carbamazepine plasmatic levels

M. Viana, L. Magliulo, M. Mula, M. G. Scordo, C. Varrasi, S. Fallarini, R. Cantello, M. L. Dahl, G. Lombardi, F. Monaco

Research output: Contribution to journalArticlepeer-review


Carbamazepine (CBZ) is the antiepileptic drug of choice for partial and tonic-clonic seizure. CBZ is metabolized by the cytochrome P450 (CYP) system, particularly the isoforms CYP3A4 and CYP3A5. A number of allelic variants have been described for CYP3A4 and CYP3A5 potentially affecting the expression/activity of the enzymes with influences on drug metabolism. In order to evaluate the impact of CYP3A polymorphisms on CBZ plasma levels, 29 epileptic patients in CBZ therapy at steady-state were genotyped for CYP3A4 (*1B, *3, *4) e and CYP3A5 (*2,*3,*6) and the CBZ plasma levels measured.

Translated title of the contributionImpact of CYP3A polymorphism on carbamazepine plasmatic levels
Original languageItalian
Pages (from-to)205-207
Number of pages3
JournalBollettino - Lega Italiana contro l'Epilessia
Issue number140
Publication statusPublished - Apr 2010

ASJC Scopus subject areas

  • Clinical Neurology


Dive into the research topics of 'Impact of CYP3A polymorphism on carbamazepine plasmatic levels'. Together they form a unique fingerprint.

Cite this